Aurobindo Pharma up 4.5%

about 1 year ago
No Image

Aurobindo Pharma went up over 4.5% to hit an intraday high at Rs.1012.90. Its 52-week high is at Rs.1063.75.

The company announced the transfer of business undertaking comprised in Unit·4, on a going concern basis, to Eugia Pharma Specialities, a wholly owned subsidiary of the company.

The transfer of the business undertaking will be done for a lumpsum consideration of Rs.876 crore. The slump sale is proposed with the objectives of integration of Unit 4 along with other units in Eugia Pharma Specialities to improve operational synergy.

The Unit 4 of the company engaged in the business of manufacture of generic injectables and Ophthalmics. In FY21, this unit contributed 6% to total turnover of the Aurobindo Pharma.

The completion of the sale is estimated in Q2FY22 and business transfer will be effective from 1st July 2021 onwards.

Popular Comments

No comment posted for this article.